145 filings
Page 3 of 8
8-K
ek5k5ke
22 Mar 23
Karuna Therapeutics Announces Proposed Public Offering of Common Stock
5:23pm
424B5
az4l6s0xdnbaserxj67j
22 Mar 23
Prospectus supplement for primary offering
4:14pm
424B5
nxc0l
20 Mar 23
Prospectus supplement for primary offering
4:35pm
8-K
67602zznz0 v2qzs
20 Mar 23
Karuna Therapeutics Announces Positive Results from Phase 3 EMERGENT-3 Trial of KarXT in Schizophrenia
6:59am
8-K
ns3kblff3ye8lnlnvk9l
10 Mar 23
Regulation FD Disclosure
3:53pm
S-8
4ocww
23 Feb 23
Registration of securities for employees
7:25am
8-K
crr1bw1r48w mb
23 Feb 23
Karuna Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Result and Provides General Business Updates
6:36am
8-K
tfplm7ts2ocq2v0oe b6
2 Feb 23
Karuna Therapeutics Announces Exclusive Global License Agreement for Goldfinch Bio’s Investigational TRPC4/5 Product Candidates
6:40am
8-K
i9pbszaefu 6x0e
5 Jan 23
Departure of Directors or Certain Officers
4:32pm
8-K
rfzls4lo21lk4s89v
6 Dec 22
Karuna Therapeutics Appoints Bill Meury as President and Chief Executive Officer
6:36am
8-K
0mb6rtsa b2l3v
3 Nov 22
Karuna Therapeutics Reports Third Quarter 2022 Financial Results and Provides General Business Updates
6:37am
8-K
e412h
11 Aug 22
Karuna Therapeutics Announces Proposed Public Offering of Common Stock
5:03pm
424B5
0t1q3mocn irwixwj
11 Aug 22
Prospectus supplement for primary offering
4:49pm
424B5
y0otl8q5edrf9js wz
8 Aug 22
Prospectus supplement for primary offering
5:18pm
8-K
3zn 03wfhl
8 Aug 22
Karuna Therapeutics Reports Second Quarter 2022 Financial Results and Provides General Business Updates
6:50am
8-K
bby24m7
8 Aug 22
Karuna Therapeutics Announces Positive Results from Phase 3 EMERGENT-2 Trial of KarXT in Schizophrenia
6:43am
8-K
6b0kxr2b8k tblzk8
21 Jun 22
Submission of Matters to a Vote of Security Holders
7:06am